Plant Comparison

Pot marigold vs Perforate St John’s-wort

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant APot marigoldCalendula officinalisAsteraceaeFull monograph →
Plant BPerforate St John’s-wortHypericum perforatumHypericaceaeFull monograph →

At a glance

Pot marigold and Perforate St John’s-wort: they share 7 indicated uses (arthritis / joint pain, bruising, eczema, …); 4 pharmacological actions in common.

Pot marigoldPerforate St John’s-wort
Constituents33
Pharmacological actions76
Indicated uses89
Safety notes22
Cited sources1731
Indicated uses
Only Pot marigold
Cancer (anticancer research)
Shared (7)
Arthritis / joint painBruisingEczemaInfection (general)Inflammation (general)Skin irritationWounds
Only Perforate St John’s-wort
Cold & fluInsomnia / sleeplessness
Pharmacological actions
Only Pot marigold
Anticancer (preclinical)AntifungalAntimicrobial
Shared (4)
Anti-inflammatoryAntioxidantEmollient / skin-soothingVulnerary (wound healing)
Only Perforate St John’s-wort
AntiviralSedative / sleep support

Evidence face-off — shared uses

ConditionPot marigoldPerforate St John’s-wortVerdict
Arthritis / joint pain5/101/10Stronger for Pot marigold
Bruising5/101/10Stronger for Pot marigold
Eczema5/101/10Stronger for Pot marigold
Infection (general)5/101/10Stronger for Pot marigold
Inflammation (general)5/101/10Stronger for Pot marigold
Skin irritation5/101/10Stronger for Pot marigold
Wounds5/101/10Stronger for Pot marigold

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Triterpene saponins (oleanolic acid glycosides, calendulosides)[1]

Principal wound-healing and anti-inflammatory constituents of the flower.

Triterpene saponinsSaponins
Flavonoids and carotenoids[4]

Antioxidant flavonoids and carotenoids give the flower its orange-yellow colour and contribute to its antioxidant activity.

FlavonoidsCarotenoids
Essential oil and resin[1]

Minor aromatic and resinous constituents of the flower head.

Essential (volatile) oil
Naphthodianthrones (hypericin, pseudohypericin)[4]

Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.

Phloroglucinols (hyperforin)[4]

Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.

Hyperforin
Flavonoids (hyperoside, quercetin, rutin)[4]

Antioxidant flavonoids contributing to overall activity.

FlavonoidsQuercetinRutin

Pharmacological Actions

Anti-inflammatory[2, 6, 8, 13, 14, 15]
Anticancer (preclinical)[2, 4, 16]

Calendula officinalis extracts show cytotoxic antitumor, pro-apoptotic and antimetastatic activity across many cancer cell lines and in animal models (preclinical).

Antifungal[13, 14, 15]
Antimicrobial[7, 13, 14, 15]
Antioxidant[4, 10, 13, 14, 15]
Emollient / skin-soothing[13, 14, 15]
Vulnerary (wound healing)[1, 5, 9, 13, 14, 15]
Anti-inflammatory[5, 15, 16]
Antioxidant[6, 15, 16]
Antiviral[15, 16]
Emollient / skin-soothing[15, 16]
Sedative / sleep support[1, 2, 4, 5, 9, 11, 12, 13, 14, 15, 16]
Vulnerary (wound healing)[4, 15, 16]

Traditional & Indicated Uses

Arthritis / joint pain[13, 14, 15]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Arthritis / joint pain
Bruising[13, 14, 15]Moderate · 5/10

inferred from vulnerary action

Evidence: 5
Label: Bruising
Cancer (anticancer research)[2, 4, 16]Good · 7/10

A Calendula officinalis (LACE) aqueous extract inhibits proliferation (70-100%) of leukemia, melanoma, breast, prostate, lung and colon cancer cell lines via G0/G1 arrest and caspase-3 apoptosis and inhibits melanoma growth in nude mice; a systematic review documents its cytotoxic and antimetastatic antitumour activity (preclinical).

Evidence: 7
Label: Cancer (anticancer research)
Eczema[13, 14, 15]Moderate · 5/10

inferred from emollient action

Evidence: 5
Label: Eczema
Infection (general)[13, 14, 15]Moderate · 5/10

inferred from antifungal action

Evidence: 5
Label: Infection (general)
Inflammation (general)[13, 14, 15]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Inflammation (general)
Skin irritation[13, 14, 15]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Skin irritation
Wounds[13, 14, 15]Moderate · 5/10

inferred from antimicrobial action

Evidence: 5
Label: Wounds
Arthritis / joint pain[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Bruising[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cold & flu[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Cold & flu
Eczema[15, 16]Traditional · 1/10

inferred from emollient action

Evidence: 1
Label: Eczema
Infection (general)[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Infection (general)
Inflammation (general)[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16]Traditional · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Wounds

Safety, Cautions & Contraindications

Safety note[13, 14, 15]Caution

Generally very safe for topical use. May cause contact dermatitis in rare cases (Asteraceae family allergy). Internal use is safe in normal doses. Avoid during pregnancy at therapeutic doses (uterine stimulant potential). Generally safe during breastfeeding for topical use.

Safety note[13, 14, 15, 17]Info

Duke (2002) rates calendula (Calendula officinalis) and notes anti-inflammatory, wound-healing (vulnerary), antifungal, and antispasmodic activities at experimental levels. Commission E (KOM) approves calendula flower for wound healing and anti-inflammatory uses, both topically and as a gargle. The plant contains flavonoids, triterpene saponins (oleanolic acid glycosides), and essential oils. Dose: 1–2 g dried flower as tea (for mouth rinse/gargle); or as cream/ointment containing 2–5% calendula extract for topical use. Duke notes that calendula is generally very well-tolerated, though Asteraceae sensitivity can occasionally cause allergic reactions (Duke, 2002).

Safety note[15, 16]Caution

Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.

Safety note[15, 16, 17]Caution

Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).

External Ids

Gbif: 5391480
Wikidata: Q145930
Gbif: 3189486
Powo: urn:lsid:ipni.org:names:433719-1
Wikidata: Q158289

Botanical Description

Aromatic annual or short-lived perennial herb with soft, hairy, oblong leaves and branching, slightly sticky stems. The flower heads are bright orange to yellow, daisy-like, with numerous narrow ray florets surrounding a darker central disc, opening in sunlight and closing at dusk.[1]

Height: 30-60 cm
Habit: Erect, branching annual or short-lived perennial herb
Leaves: Soft, hairy, oblong to lance-shaped
Flowers: Bright orange to yellow, daisy-like flower heads with numerous narrow ray florets
Stem: Branching, softly hairy, slightly sticky
Root: Shallow taproot
Fruit: Curved, ridged achene, without pappus
Flowering Period: June to first frost

Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]

Height: 30-90 cm
Habit: Erect, branching perennial herb
Leaves: Paired, oval, dotted with tiny translucent oil glands
Flowers: Bright yellow, five-petalled, with numerous stamens and black-dotted petal edges, in flat-topped clusters
Stem: Erect, branching, with two raised longitudinal ridges
Root: Woody rootstock with spreading rhizomes
Fruit: Small, three-valved capsule
Flowering Period: June-September (traditionally around St John's Day, 24 June)

Habitat

Widely cultivated as a garden and medicinal plant; believed native to southern Europe and the Mediterranean, now naturalised in gardens and waste ground worldwide.[1]

Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]

Harvesting

The flower heads (or just the ray-floret petals) are picked by hand as they open, through the flowering season, and dried quickly in a warm, shaded, airy place to preserve colour and resin content.[1]

Parts: Flower, Petals
Season: Through the flowering season (summer to autumn), as flowers open

The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]

Parts: Flower, Leaf
Season: Summer, at flowering

Traditional Uses

Calendula flower is one of the most widely used topical wound-healing and skin-soothing herbs in Western herbal medicine, applied to cuts, grazes, minor burns and skin inflammation, and used internally as a gentle anti-inflammatory and antimicrobial remedy and as a gargle for mouth and throat irritation.[1]

St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]

Preparations

Infused oil[1]

Dried petals infused in a carrier oil, used as a soothing base for topical creams and balms for skin healing.

Cream/ointment[1]

Standardised flower extract formulated into a cream or ointment for topical wound and skin care; the best-studied modern form.

Infusion[12]

Dried flower infused in hot water, 1-2 g in 150 ml, used still warm as a mouth rinse or gargle 2-4 times daily. The EU herbal monograph's posology for this preparation is OROMUCOSAL only - it does not support taking the infusion internally. Educational reference only, not a prescription.

Standardised extract[1]

Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.

Dosage

Topical cream/ointment[12]

The EU herbal monograph gives semi-solid preparations containing the equivalent of 2-10% herbal substance, applied as a thin layer to the affected area 2 to 4 times daily. Educational reference only, not a prescription.

Infusion/gargle[12]

The EU herbal monograph gives 1-2 g of the flower in 150 mL water as an infusion, used still warm for rinsing and gargling 2 to 4 times daily, or to prepare impregnated dressings for the skin. This is an oromucosal and cutaneous preparation, not an oral tea. Educational reference only, not a prescription.

Standardised extract[1]

Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.

References

REF-0752, REF-0753, REF-0754, REF-2124, REF-2125, REF-2126, REF-2127, REF-2128, REF-2129, REF-2130, REF-2131
REF-0842, REF-0843, REF-0844, REF-1789, REF-1790, REF-1791, REF-1792, REF-1793, REF-1794, REF-1795, REF-1796, REF-1797, REF-1798, REF-1799

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

Drug Class Interactions

Not documented

Safety note[18, 19, 20, 21]Avoid
Drug Class: antidepressants-serotonergic
Mechanism: St John's wort raises serotonin activity; combined with SSRIs, SNRIs or MAOIs it can trigger serotonin syndrome (agitation, tremor, sweating, rapid heartbeat). Reviews of clinical reports document serotonin syndrome and lethargy when it is combined with serotonin-reuptake inhibitors.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 22]Avoid
Drug Class: antiretrovirals
Mechanism: Potent CYP3A4 and P-glycoprotein induction lowers antiretroviral levels (indinavir exposure fell ~57%), risking loss of viral control and drug resistance.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 23]Avoid
Drug Class: immunosuppressants
Mechanism: Enzyme and transporter induction reduces ciclosporin and tacrolimus levels; reported to cause subtherapeutic concentrations and transplant rejection.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 24, 25, 26]Avoid
Drug Class: hormonal-therapies
Mechanism: Increased metabolism of ethinylestradiol and progestins reduces contraceptive exposure, causing breakthrough bleeding, ovulation and unplanned pregnancy. Randomised and controlled trials in women confirmed more breakthrough bleeding, reduced progestin levels and evidence of ovulation when St John's wort was added to the pill.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: CYP induction increases warfarin clearance and can lower INR, reducing the anticoagulant effect; close monitoring is needed.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 27]Caution
Drug Class: cardiac-glycosides
Mechanism: P-glycoprotein induction lowers digoxin levels (AUC fell ~25% over ten days), which may reduce its effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: statins
Mechanism: CYP3A4 induction lowers levels of simvastatin and atorvastatin, potentially weakening their cholesterol-lowering effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: cyp3a4-substrates
Mechanism: As a broad CYP3A4 and P-glycoprotein inducer, St John's wort can lower levels of many medicines cleared by this pathway; check each medication individually.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[20, 28, 29]Avoid
Drug Class: chemotherapy-agents
Mechanism: St John's wort strongly induces CYP3A4 and P-glycoprotein, speeding the breakdown and removal of several cancer medicines. In patients it cut the active form of irinotecan (SN-38) by about 42% and reduced imatinib exposure by roughly a third - enough to weaken treatment and risk drug resistance. Do not take St John's wort during chemotherapy.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Pairings

Not documented

St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]

Partner Id: crocus-sativus
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]

Partner Id: rhodiola-rosea
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]

Partner Id: valeriana-officinalis
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]

Partner Id: piper-methysticum
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

References & Sources

  1. Givol, O., Kornhaber, R., Visentin, D., Cleary, M. et al (2019) 'A systematic review of Calendula officinalis extract for wound healing', Wound Repair and Regeneration, 27(5), pp. 548-561. doi:10.1111/wrr.12737 Meta-analysis / review
    https://doi.org/10.1111/wrr.12737
  2. Shahane, K., Kshirsagar, M., Tambe, S., Jain, D. et al (2023) 'An Updated Review on the Multifaceted Therapeutic Potential of Calendula officinalis L', Pharmaceuticals (Basel), 16(4), pp. 611. doi:10.3390/ph16040611 Traditional / reference
    https://doi.org/10.3390/ph16040611
  3. Saffari, E., Mohammad-Alizadeh-Charandabi, S., Adibpour, M., Mirghafourvand, M. et al (2016) 'Comparing the effects of Calendula officinalis and clotrimazole on vaginal Candidiasis: A randomized controlled trial', Women & Health, 57(10), pp. 1145-1160. doi:10.1080/03630242.2016.1263272 Randomized trial
    https://doi.org/10.1080/03630242.2016.1263272
  4. Cruceriu, D., Balacescu, O. and Rakosy, E (2018) 'Calendula officinalis: potential roles in cancer treatment and palliative care', Integrative Cancer Therapies, 17(4), pp. 1068-1078. doi:10.1177/1534735418803766 Meta-analysis / review
    https://doi.org/10.1177/1534735418803766
  5. Rezai, S., Rahzani, K., Hekmatpou, D. and Rostami, A (2023) 'Effect of oral Calendula officinalis on second-degree burn wound healing', Scars, Burns & Healing, 9, pp. 20595131221134053. doi:10.1177/20595131221134053 Randomized trial
    https://doi.org/10.1177/20595131221134053
  6. Kadowaki, W., Miyata, R., Mizuno, S., Fujinami, M., Sato, Y. and Kumazawa, S (2023) 'Prenylated acetophenones from the roots of Calendula officinalis and their anti-inflammatory activity', Bioscience, Biotechnology, and Biochemistry, 87(7), pp. 683-687. doi:10.1093/bbb/zbad042 Preclinical
    https://doi.org/10.1093/bbb/zbad042
  7. Samra, R.M., Maatooq, G.T. and Zaki, A.A (2022) 'A new antiprotozoal compound from Calendula officinalis', Natural Product Research, 36(22), pp. 5747-5752. doi:10.1080/14786419.2021.2023868 Preclinical
    https://doi.org/10.1080/14786419.2021.2023868
  8. Kaur, J., Sidhu, S., Chopra, K. and Khan, M.U (2016) 'Calendula officinalis ameliorates l-arginine-induced acute necrotizing pancreatitis in rats', Pharmaceutical Biology, 54(12), pp. 2951-2959. doi:10.1080/13880209.2016.1195848 Preclinical
    https://doi.org/10.1080/13880209.2016.1195848
  9. Aro, A.A., Perez, M.O., Vieira, C.P., Esquisatto, M.A.M., Rodrigues, R.A.F., Gomes, L. and Pimentel, E.R (2014) 'Effect of Calendula officinalis cream on achilles tendon healing', Anatomical Record, 298(2), pp. 428-435. doi:10.1002/ar.23057 Preclinical
    https://doi.org/10.1002/ar.23057
  10. Zhang, X., Wang, R., Finiuk, N., Stoika, R., Lin, H., Wang, X. and Jin, M (2023) 'Active compounds from Calendula officinalis flowers act via PI3K and ERK signaling pathways to offer neuroprotective effects against Parkinson's disease', Food Science & Nutrition, 12(1), pp. 450-458. doi:10.1002/fsn3.3792 Preclinical
    https://doi.org/10.1002/fsn3.3792
  11. Kadowaki, W., Miyata, R., Fujinami, M., Sato, Y. and Kumazawa, S (2023) 'Catechol-O-methyltransferase inhibitors from Calendula officinalis leaf', Molecules, 28(3), pp. 1333. doi:10.3390/molecules28031333 Preclinical
    https://doi.org/10.3390/molecules28031333
  12. European Medicines Agency (HMPC) (2018) 'European Union herbal monograph on Calendula officinalis L., flos, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf Traditional / reference
    https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf
  13. Hoffmann, D (2003) 'Medical Herbalism'. Traditional / reference
    https://scholar.google.com/scholar?q=Medical%20Herbalism
  14. Nicolaus, C. et al (2017) 'A double-blind, randomized controlled trial to investigate the efficacy and safety of a monograph-based Calendula cream versus a comparator cream', 35(1), pp. 81--89. Randomized trial
    https://scholar.google.com/scholar?q=A%20double-blind%2C%20randomized%20controlled%20trial%20to%20investigate%20the%20efficacy%20and%20safety%20of%20a%20monograph-based%20Calendula%20cream%20versus%20a%20comparator%20cream
  15. Preethi, K.C. and Kuttan, R (2009) 'Wound healing activity of flower extract of Calendula officinalis', 20(1), pp. 73--79. doi:10.1515/jbcpp.2009.20.1.73 Preclinical
    https://doi.org/10.1515/jbcpp.2009.20.1.73
  16. Jimenez-Medina, E. and Garcia-Lora, A. and Paco, L. and Algarra, I. and Collado, A. and Garrido, F (2006) 'A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation', BMC Cancer, 6, pp. 119. doi:10.1186/1471-2407-6-119 Preclinical
    https://doi.org/10.1186/1471-2407-6-119
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  1. Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
    https://doi.org/10.1016/j.jad.2016.12.048
  2. Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
    https://doi.org/10.1007/s00210-022-02229-z
  3. Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
    https://doi.org/10.1016/S0140-6736(99)06457-0
  4. Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
    https://doi.org/10.22038/IJBMS.2022.65112.14338
  5. Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
    https://doi.org/10.1016/j.phymed.2024.155847
  6. Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
    https://doi.org/10.3389/fpls.2016.01004
  7. Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
    https://doi.org/10.1002/ptr.5050
  8. Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2010.07.034
  9. Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
    https://doi.org/10.1016/j.lfs.2004.04.005
  10. Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
    https://doi.org/10.3109/13697137.2013.861814
  11. Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
    https://doi.org/10.2165/00003088-200645050-00002
  12. Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
    https://doi.org/10.1055/s-2001-15467
  13. Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
    https://doi.org/10.1038/sj.mp.4000557
  14. Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
    https://doi.org/10.2174/1568026033392589
  15. Linde, K. et al (2008) 'St John'. Traditional / reference
    https://scholar.google.com/scholar?q=St%20John
  16. Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
    https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  18. Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
    https://doi.org/10.1177/0269881104042632
  19. Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
    https://doi.org/10.2165/11317010-000000000-00000
  20. Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
    https://doi.org/10.1208/s12248-009-9146-8
  21. Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
    https://doi.org/10.1111/bph.14936
  22. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
    https://doi.org/10.1016/S0140-6736(99)05712-8
  23. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
    https://doi.org/10.1345/aph.10088
  24. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  25. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  26. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
    https://doi.org/10.1046/j.1365-2125.2003.02005.x
  27. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
    https://doi.org/10.1053/cp.1999.v66.a101944
  28. Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
    https://doi.org/10.1093/jnci/94.16.1247
  29. Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
    https://doi.org/10.1592/phco.24.16.1508.50958
  30. Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
    https://doi.org/10.5414/cpp42139
  31. Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
    https://doi.org/10.3390/ph19030399

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.